Internal Medicine, Rheumatology · Brighton, MI
NPI
1750482162
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
10484 Citation Dr, Suite 100
Brighton, MI, 48116
Phone (810) 225-7553
Groups this clinician bills Medicare through
Medicare paid, 2024
$883K
57,016 services
Medicare patients, 2024
305
Average age 72
Drug cost, 2024
$5.0M
3,081 prescriptions
Company payments, 2024
$131
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James E Dowd was code J3262 (injection, tocilizumab, 1 mg), 23,680 times for 11 patients. In total James E Dowd billed 57,016 services in 22 codes, and Medicare paid $883K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 23,680 | 11 | $4.55 | $108K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 11,977 | 19 | $33.29 | $399K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 9,100 | 12 | $9.06 | $82K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 3,410 | 21 | $24.87 | $85K |
| J0897 Injection, denosumab, 1 mg | Office | 1,440 | 15 | $20.40 | $29K |
| Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 1,320 | 11 | $23.37 | $31K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 534 | 263 | $11.57 | $6,178 |
| 99214 Office E&M - Established | Office | 509 | 214 | $84.64 | $43K |
| 96413 Chemotherapy Administration | Office | 400 | 58 | $92.05 | $37K |
| 96415 Chemotherapy Administration | Office | 136 | 25 | $20.27 | $2,756 |
| 99213 Office E&M - Established | Office | 107 | 80 | $58.22 | $6,229 |
| 99204 Office E&M - New | Office | 61 | 61 | $113.56 | $6,927 |
| 96401 Chemotherapy Administration | Office | 37 | 16 | $51.83 | $1,918 |
By year: 2022 $494K for 27,649 services; 2023 $671K for 39,821 services; 2024 $883K for 57,016 services.
Medicare prescription drug claims, 2024
In 2024, the drug James E Dowd prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 567 prescriptions and refills. In total James E Dowd wrote 3,081 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 567 | 1,295 | 151 | $25K |
| Prednisone Generic | 301 | 500 | 98 | $3,156 |
| Hydroxychloroquine Sulfate Generic | 235 | 641 | 66 | $14K |
| Allopurinol Generic | 223 | 581 | 67 | $3,752 |
| Alendronate Sodium Generic | 159 | 402 | 49 | $1,914 |
| Enbrel Sureclick Etanercept | 141 | 142 | 15 | $1.0M |
| Leflunomide Generic | 140 | 393 | 47 | $11K |
| Enbrel Etanercept | 121 | 142 | 14 | $992K |
| Humira(Cf) Pen Adalimumab | 90 | 90 | Under 11 | $593K |
| Humira(Cf) Adalimumab | 68 | 78 | Under 11 | $521K |
| Gabapentin Generic | 61 | 141 | 17 | $913 |
| Insulin Syringe Syringe And Needle,insulin,1ml | 53 | 122 | 21 | $294 |
| Folic Acid Generic | 41 | 123 | 16 | $571 |
| Colchicine Generic | 41 | 77 | 14 | $2,317 |
| Methotrexate Sodium Methotrexate Sodium/Pf | 39 | 63 | 17 | $732 |
Brand drugs: 865 claims; generic drugs: 2,115 claims; opioid claims: 97.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid James E Dowd $131 ($131 in general payments such as food, travel and fees) from 6 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $31.72.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.